ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Trial Details

NCT ID

NCT06460298

Phase

PHASE1 / PHASE2

Sponsor

ProDa BioTech, LLC

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• ProAgio Dose Levels (DL) 1,2,3,4
• ProAgio Dose Expansion

Locations (sample)

• Atlanta, Georgia, United States|33.749,-84.38798
• Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

• Adult participants, ≥ 18 years of age, with histologically or cytologically confirmed metastatic breast cancer that is estrogen receptor (ER) negat…
• Participants must have received at least two lines of prior systemic treatment for advanced disease. If participants received systemic therapy in t…
• ECOG performance status ≤2
• Participants must have adequate organ and marrow function as defined below:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.